Strengthening the Pharmacovigilance System in Mexico: Implementation of VigiFlow and VigiLyze, as ICSR and Signal Detection Management Systems

• Published in: Pharmaceutical medicine Vol. 37; no. 6; pp. 425 - 437
• Main Authors: Rayón-Ramírez, Gandi, Alvarado-López, Salvador, Camacho-Sandoval, Rosa, Loera, Miriam J., Svarch, Alejandro E., Alcocer-Varela, Jorge
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01-11-2023; Springer Nature B.V
• Subjects: Biomedical and Life Sciences; Biomedicine; Health facilities; Immunization; Leading Article; Pharmaceutical Sciences/Technology; Pharmacology/Toxicology; Pharmacotherapy; Pharmacovigilance; Responsible persons; Vaccines; Mexico
• ISSN: 1178-2595; 1179-1993
• DOI: 10.1007/s40290-023-00490-y

Pharmacovigilance (PV) activities aim to identify potential risks of medicines and vaccines after they have been authorised in the market by collecting and analysing information on suspected adverse events from different stakeholders. These can be captured and transmitted electronically in the form of Individual Case Safety Reports (ICSRs). Hence, up-to-date ICSRs management systems, like VigiFlow and signal detection and management systems as VigiLyze, have an important role in the PV system of a country. In 2019, after various attempts to establish a PV database that could fulfil the needs of the country, Mexico’s National Regulatory Authority, COFEPRIS (Federal Commission for the Prevention against Sanitary Risks) decided to implement these tools. This has been a successful project that is still ongoing, it has involved national and international organisations, and has required the participation and integration of different components of the national PV system. The implementation of these tools has allowed COFEPRIS to increase its reporting trends and quality of reporting, while contributing to make more efficient interactions and processes with PV stakeholders, even during the COVID-19 pandemic. It has also allowed them to strengthen their commitment to the WHO-Programme for International Drug Monitoring, while highlighting opportunities for improvement in the national PV scenario and in the PV tools themselves. The aim of this article is to describe the implementation process, give an overview of current results regarding ICSR data and processes, and highlight the achievements, challenges, and opportunities for improvement after the three years since the beginning of the project.